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Focus Article
Cell cycle RNA regulons
coordinating early
lymphocyte development
Alison Galloway1 and Martin Turner2*
Lymphocytes undergo dynamic changes in gene expression as they develop from
progenitor cells lacking antigen receptors, to mature cells that are prepared to
mount immune responses. While transcription factors have established roles in
lymphocyte development, they act in concert with post-transcriptional and post-
translational regulators to determine the proteome. Furthermore, the post-
transcriptional regulation of RNA regulons consisting of mRNAs whose protein
products act cooperatively allows RNA binding proteins to exert their effects at
multiple points in a pathway. Here, we review recent evidence demonstrating
the importance of RNA binding proteins that control the cell cycle in lymphocyte
development and discuss the implications for tumorigenesis. © 2017 The Authors.
WIREs RNA published by Wiley Periodicals, Inc.
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INTRODUCTION
Lymphocytes are the cells responsible for adaptiveimmunity in vertebrates. B cells are the subset of
lymphocytes uniquely producing antibodies (secreted
immunoglobulins) and recognize antigens through
their B cell receptors (BCRs, transmembrane immu-
noglobulins). In mammals B cells continuously
develop from haematopoietic stem cells in the bone
marrow throughout adulthood to sustain the mature
pool of antigen inexperienced (naïve) B cells. T cells
are lymphocytes that recognize antigenic determi-
nants that have been processed and presented by
antigen presenting cells through their T cell receptors
(TCRs). T cells provide cell-mediated immunity and
help B cells produce antibodies. T cells develop from
progenitor cells that have migrated from the bone
marrow to the thymus.
Developing B and T cells must execute V(D)J
recombination of the DNA encoding immunoglobu-
lin heavy and light chain or of the TCRα and TCRβ
loci respectively to produce diverse receptor speciﬁci-
ties while avoiding inappropriate DNA damage and
maintaining genome integrity. Lymphocytes that pro-
duce functional antigen receptors with nonself-
speciﬁcities must be positively selected while those
producing non-functional proteins or self-reactive
speciﬁcities must be removed. Furthermore, lympho-
cytes must adapt to a number of distinct niches as
they migrate within the bone marrow, blood, spleen,
lymph nodes, and other tissues in a developmental
stage appropriate manner. To mediate these pro-
cesses, developing lymphocytes are known to
respond to environmental and developmental cues
through signal transduction pathways activated by
cytokine/chemokine, adhesion receptors and the anti-
gen receptor or its precursor (the pre-BCR or the pre-
TCR). These regulate gene expression through the
expression and activation of developmental stage-
speciﬁc transcription factors.1 However, it is becom-
ing increasingly apparent that the gene regulatory
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networks that control lymphocyte development also
require the activity of factors that act post-
transcriptionally on RNA. These regulatory networks
allow the integration of signaling pathways with the
control of mRNA transcription, processing, stability,
and localisation.
Post-transcriptional control of gene expression
is mediated by RNA binding proteins (RBPs) and
non-coding RNAs. Although microRNAs have
important roles in lymphocyte development, this
review will focus on the role of RBP in early lym-
phoid development as this topic has received less
attention. Regulation through RBP allows signaling
events to rapidly inﬂuence the fate of existing coding
and non-coding RNAs, thus avoiding the lag time
associated with transcriptional changes, and allowing
a more diverse and dynamic range of molecular out-
comes. Co-regulated RNAs may comprise sets of
transcripts mediating a common function and have
been termed RNA regulons.2 These can be controlled
concurrently by signaling events allowing the cell to
coordinate within and between biological processes
that might otherwise be considered distinct if they
are not coordinately regulated by transcriptional or
epigenetic mechanisms. RBP have emerged as a fre-
quent constituent of the proteome and many different
protein domains can interact with RNA in a
sequence-speciﬁc or -nonspeciﬁc manner with varying
afﬁnities.3 The mRNA expression of ﬁve RBPs dis-
cussed in this review during B and T lymphocyte
development is shown in Figure 1, this data was
extracted from the immgen immunological genome
database.4 The RBP-encoding mRNAs shown:
Zfp36, Zfp36l1, Zfp36l2, Elavl1, and Cnot3 are
broadly expressed throughout the early stages of
lymphocyte development and may exert their effects
at many distinct stages.
Amongst sequence elements recognized by spe-
ciﬁc RBPs, the AU-rich element (ARE), which has the
consensus sequence WWAUUUAWW, where W may
be U or A, is one of the best studied. AREs are pres-
ent in as many as 10% of human mRNAs5 and inter-
act with a variety of different RNA binding domains.
This may allow several RBP to act in concert while
decoding cellular signals. Figure 2 demonstrates how
AREs are prevalent in the 30UTRs of mRNAs encod-
ing factors involved in cell cycle progression; note
that the UTRs often make up a signiﬁcant proportion
of the transcript suggesting that there could be fur-
ther regulatory sequences encoded there. Additional
regulatory potential may also arise from interactions
between the different ARE-binding proteins, and
other transacting factors such as microRNAs. In this
manuscript, we will discuss recent progress
identifying RBP and RNA regulons that contribute to
B and T cell development and consider whether these
ﬁndings have broader relevance to non-lymphoid sys-
tems and malignancy.
EARLY B CELL DEVELOPMENT
V(D)J recombination is a process of somatic gene
rearrangement unique to lymphocytes where variable
(V), diversity (D), and joining (J) gene segments,
encoding the complementarity determining regions of
the antigen receptors, are recombined by the activity
of the recombination activating genes (RAG) to form
different coding sequences resulting in a large num-
ber of receptor speciﬁcities. This allows generation
of a diverse repertoire of B and T cells each able to
recognize a unique antigen. In B cell development,
V(D)J recombination generally occurs ﬁrst at the
immunoglobulin heavy chain (IgH) locus with D to J
recombination which is complete at the pre-pro-B cell
stage of development (Figure 3). Next, V to DJ
recombination occurs in a subset of quiescent pro-B
cells. When this generates a functional Igμ protein
capable of forming a complex with the surrogate
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FIGURE 1 | Expression of mRNAs encoding RNA binding proteins
in early lymphocyte development. Relative expression of selected
mRNAs has been extracted from the immgen database. Source: http:
//www.immgen.org. Bars represent the mean, and error bars show the
standard deviation of three measurements.
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light chains (VpreB and λ5), a cell-surface signaling
receptor, termed the precursor B cell receptor (pre-
BCR), is formed that both promotes a limited, but
very vigorous burst of proliferation of the early pre-B
cell, and, through a feedback mechanism, the transi-
tion to the late pre-B cell stage.6 Expression of the
pre-BCR induces the transcription factor c-Myc,
which in turn represses p27 (Cdkn1b) transcription
and enhances the transcription of Cyclin D3, which
activates CDK-4 and -6 to drive cell cycle progres-
sion in early pre-B cells.7 A later wave of gene
expression induced by the pre-BCR re-establishes
quiescence in late pre-B cells allowing immunoglobu-
lin light chain recombination at the Igλ or Igκ loci to
occur. The transcription factors Aiolos and Ikaros,
which repress c-Myc, are induced and the Dyrk1a
kinase limits the expression of Cyclin D3 at this
stage.8,9 Expression of a light chain leads to the
expression of the BCR at the beginning of the imma-
ture B cell stage where cells are quiescent and
undergo positive and negative selection for appropri-
ate receptor speciﬁcities before maturing into naïve B
cells. Cells that fail to produce either the heavy or
light immunoglobulin chain are eliminated by
apoptosis.
The deliberate introduction of DNA strand
breaks (DSBs) and the joining of the resected DNA
carries the risk that the DNA will not be repaired
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FIGURE 2 | mRNA structure and AU-rich elements (AREs) within mouse mRNAs encoding factors involved in the G1-S transition in the cell
cycle. The proportion of each transcript that is 50 UTR (blue), coding DNA sequence (CDS; red) and 30 UTR (yellow) is shown. AREs in the 3’UTR
with the sequence ‘WWAUUUAWW’ where W can be either U or A are marked with black symbols. Transcript information was downloaded from
the Ensembl project of genome databases with BioMart software. Where genes were annotated with alternative UTRs or CDS, the longest
sequence was selected.
WIREs RNA Cell cycle RNA regulons
© 2017 The Authors. WIREs RNA published by Wiley Periodicals, Inc. 3 of 15
correctly and it is known that chromosomal transloca-
tions and other aberrations do occur in some cells at
this stage of development.10,11 To minimize this risk,
robust mechanisms exist to coordinate V(D)J recombi-
nation and cell cycle progression. Signaling through
the IL7-receptor (IL7R) activates STAT5 to repress
RAG transcription in proliferating pro-B cells thus reg-
ulating IL7 availability or responsiveness allows the
processes to occur in discrete populations.12 Further-
more, the RAG2 protein is phosphorylated by cyclin
dependent kinase (CDK)-2 during the G1-S phase tran-
sition leading to its ubiquitination and degradation
thus avoiding entry into S phase with the potential to
generate RAG-mediated DSBs.13
THE ROLE OF THE ZFP36 FAMILY IN
EARLY B CELL DEVELOPMENT
Recent evidence suggests that the transcriptional and
signaling pathways regulating processes that co-
ordinate the dynamic proliferation of developing B
and T cells are integrated with post-transcriptional
mechanisms mediated by the ZFP36 family RBP. The
ZFP36 family bind to AREs in the 30UTR of their
target mRNAs through a conserved CCCH-zinc ﬁn-
ger structure and recruit deadenylases and decapping
enzymes to destabilize their targets.14 The ability of
these RBP to repress gene expression has been best
understood from the study of ZFP36 in the context
of cytokine gene expression and inﬂammation.15,16
Less is known about the related ZFP36L1 and
ZFP36L2, but studies using conditional mutagenesis
in the mouse demonstrate these genes act in a highly
redundant manner in developing B and T cells to
limit proliferation.17–19
The mechanistic insight into this process was
revealed by the application of individual nucleotide
crosslinking and immunoprecipitation (iCLIP) for
ZFP36L1. These experiments performed on mitogen
activated mature B cells (which bear overlap in their
transcriptomes with proliferating pro-B cells) demon-
strated ZFP36L1 bound to AREs in the 30UTRs of a
group of mRNAs encoding proteins involved in the
G1-S transition.18 Since the proteins encoded by
ZFP36L1 targets act in a cooperative manner to acti-
vate the E2F pathway that drives cell cycle progres-
sion, and are coordinately regulated by a
post-transcriptional mechanism at the mRNA level
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FIGURE 3 | Early stages of B and T lymphocyte development. Important processes during B and T cell development are shown, with the
corresponding stages of development. Stages of T cell development are abbreviated to double negative (DN), double positive (DP), and single
positive (SP). Brieﬂy, progenitor B and T cells rearrange their IgH or Tcrβ loci respectively, undergo proliferative selection, then rearrange their
Igκ/λ or Tcrα loci to form unique antigen receptors.
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they can be considered an RNA regulon (Figure 4).
The E2F pathway has a characteristic switching
behavior caused by positive feedback; once a thresh-
old of signaling has been reached the G1-S transition
is irreversibly triggered.20 The classical E2Fs (E2F1,
E2F2, and E2F3) are repressed by retinoblastoma
protein (Rb) and this inhibition is relieved when Rb
is phosphorylated by the CDKs. Once activated, the
classical E2Fs drive transcription of Cyclin E and the
phosphatase CDC25A which activates CDK2, thus
further increasing Rb phosphorylation.21
Overexpression of the RNA regulon repressed
by ZFP36L1 and ZFP36L2 ampliﬁes the sensitivity
of the E2F pathway thus tipping the balance towards
S phase entry and leading to activation of the
mechanisms which prevent V(D)J recombination
from occurring. The V(D)J recombination defect in
Zfp36l1 Zfp36l2 KO pro- and pre-B cells was res-
cued by administration of the CDK4/6 inhibitor pal-
bociclib. Conditional overexpression of a
GFPZFP36L1 fusion protein inhibited the prolifera-
tion of pre-B cells. Thus Zfp36l1 and Zfp36l2 are
necessary to establish a quiescent state permissive for
V(D)J recombination in pro-B and pre-B cells. Fur-
thermore, the increased proliferation of Igμ-negative
pro-B cells led to defective selection as loss of
Zfp36l1 and Zfp36l2 allowed some Igμ-negative cells
to express the pre-B cell marker CD25 indicating that
they had bypassed the pre-BCR checkpoint. How-
ever, these cells were apoptotic indicating they had
not received the survival signals provided by the
pre-BCR.
The regulation of cell cycle mRNAs by ZFP36
family proteins provides a mechanism by which
developing B cells may rapidly change their behavior
according to signals from the pre-BCR and IL7R.
Phosphorylation of ZFP36L1 by protein kinase B
(PKB) downstream of PI3kinase signaling and
through the P38 MAPKAPK2 kinase pathway could
repress its ability to promote RNA decay.22–24 IL7R
signaling activates PI3K and the pre-BCR signals
through the P38 pathway which could provide a
mechanism through which these surface receptors
release the ZFP36L1/2-mediated inhibition of
mRNAs encoding the factors required for S phase
entry.25 The direct demonstration of these hypotheti-
cal links between signaling and RBP in early B cell
development will require the development and appli-
cation of tools and technologies such as phospho-
speciﬁc antibodies and proteomics. In addition,
Zfp36 and Zfp36l1 are transcriptionally repressed by
c-Myc, which is transcribed following IL7R or pre-
BCR signaling providing a further mechanism for
regulation of these RBP during early B cell develop-
ment.26 Although kinase and transcription factor tar-
gets may differ between different cell types,
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FIGURE 4 | Regulation of the cell cycle by multiple targets of ZFP36L1/L2. ZFP36L1/L2 targets [deduced by AU-rich element (ARE) sequences
in the 30UTR or by appearance in ZFP36L1 iCLIP] are shown. Proteins in blue had increased expression in Zfp36l1 Zfp36l2 KO lymphocytes (either
mRNA or protein). P27 in yellow had decreased protein in Zfp36l1 Zfp36l2 KO lymphocytes. RB1 in gray was unchanged. Interactions between
ZFP36L1/L2 targets allow them to cooperate to drive progression into the S phase of the cell cycle.
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according to variables such as the subcellular com-
partmentalisation of proteins and chromatin accessi-
bility, it seems likely that these signaling pathways
help to coordinate the cell division cycle with signal-
ing through ZFP36-family RBP. As the cell cycle is
also regulated by other RBP and at the level of
mRNA translation, it will be important to establish if
additional RBP regulates the cell cycle in developing
B cells.27
THYMIC DEVELOPMENT
T cells develop in the thymus in an analogous man-
ner to B cell development (Figure 3). The TCR is
formed from two proteins expressed following V(D)J
recombination of the TCRα and TCRβ loci. TCRβ is
recombined ﬁrst and forms the pre-TCR that pro-
motes proliferation and differentiation of T cell pro-
genitors at the β-selection checkpoint. Conditional
KO of Zfp36l1 and Zfp36l2 in the T cell lineage
leads to the development of T cell acute lymphoblas-
tic leukemia.19 Prior to the onset of malignancy
Zfp36l1 and Zfp36l2 play roles in early T cell devel-
opment that are very similar to those in B cell devel-
opment. Thus, in the T cell lineage, Zfp36l1 and
Zfp36l2 limit proliferation to those cells that have
productively rearranged the TCRβ and thus enforce
the β-selection checkpoint.17 iCLIP for ZFP36L1 on
total mouse thymocytes combined with RNAseq
analysis demonstrated that transcripts promoting the
G1-S transition are also a major regulated pathway
in these cells. Transcriptomic analysis of the DN3
population (equivalent to pro- and early pre-B cells)
demonstrated that the DN3 cells from Zfp36l1
Zfp36l2 double conditional KOs resembled post
β-selection cells (termed DN3b) more than the quies-
cent pre-selection DN3a cells despite not expressing
the TCRβ protein. Since DN3b cells are proliferating,
the DN3b transcriptional proﬁle includes expression
of cell cycle regulators involved in the G1-S transi-
tion, providing further evidence of the control of this
RNA regulon by ZFP36L1 and ZFP36L2. NOTCH1
is an important target of ZFP36L1 and ZFP36L2
which is required for driving leukaemogenesis in their
absence.19 In the β-selection checkpoint NOTCH1
helps drive proliferation by supporting cellular
metabolism by inducing factors including the glucose
transporter GLUT1, amino acid transporter CD98
and iron transporter CD71/TFR1.28,29 ZFP36 also
regulates CD71/TFR1 directly in mouse embryonic
ﬁbroblasts, thus the ZFP36 family may help coordi-
nate cell cycle and metabolic regulation around the
β-selection checkpoint.30 Notably, as observed in the
analogous stages of B cell development, loss of
Zfp36l1 and Zfp36l2 cannot provide all the signals
required for β-selection. Pre-TCR signaling increases
expression of the IL7R, rendering the cells more
responsive to IL-7,31 the Zfp36l1 Zfp36l2 double
conditional KO DN3 cells do not upregulate the
IL7R pathway and are more apoptotic than controls.
The increased proliferation of Zfp36l1 Zfp36l2
DCKO DN3 cells was linked to an increased rate of
differentiation consistent with ﬁndings that differenti-
ation is linked to the numbers of cell divisions during
T cell development.32 Zfp36l1 Zfp36l2 cKO DN3
thymocytes were also found to have increased
γH2AX, which marks double strand breaks, and
increased phosphorylation of substrates of the
ATM/ATR kinases that initiate the DNA damage
checkpoint. Despite this, it remains unclear whether
the DCKO cells actually have increased DNA dam-
age or whether the DNA damage response is more
activated per se and it is possible that the phospha-
tases that regulate γH2AX may be less active in the
DCKO cells. If DNA damage itself is increased, this
may contribute to the oncogenic transformation of
Zfp36l1 Zfp36l2 cKO thymocytes into T-ALL.
Unlike the situation in developing B cells, the
DNA damage response is able to promote the devel-
opmental progression of DN3 thymocytes, and irra-
diation can do so in the absence of TCRβ, the
obligate progression factor.33 Moreover, p53 acts as
a barrier to the developmental progression of DN3
thymocytes and it too enforces the β-selection check-
point.34 Some evidence exists to suggest that in thy-
mocytes ZFP36L1 may regulate the DDR and p53
pathways as ZFP36L1 bound to several mRNAs
whose protein products had roles in the sensing or
resolution of DNA damage, however a direct contri-
bution of these RBP to the DNA damage response of
thymocytes has not yet been established. The ubiqui-
tin ligase MDM2 was increased in DN3 cells lacking
Zfp36l1 and Zfp36l2. Mdm2 transcript was
increased in these cells, as well as late pre-B cells
from the B cell DCKO and Mdm2 mRNA was bound
by ZFP36L1 in both thymocytes and B cells. Thus,
Mdm2 is likely a direct target of ZFP36l1 and
ZFP36L2. MDM2 is a negative regulator of P53 so
ZFP36L1 and ZFP36L2 may enhance P53 responses
in B and T cell progenitors during the periods in
which cell cycle progression is being inhibited and
V(D)J recombination is occurring. The DSBs caused
by V(D)J recombination induce p38 signaling35
which inhibits ZFP36 family RBP, thus we speculate
that this mechanism may feedback to decrease p53
activation and prepare the cells for cell cycle progres-
sion once the DNA is repaired.
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Although there was evidence of increased
DNA damage checkpoint signaling in thymocytes
lacking Zfp36l1 and Zfp36l2, there was no evidence
of a P53 transcriptional response in DN3 thymo-
cytes or late pre-B cells lacking Zfp36l1 and
Zfp36l2. P21 (Cdkn1a) mRNA, a well-known p53
target, was elevated in DN3 thymocytes and late
pre-B cells lacking Zfp36l1 and Zfp36l2, however,
this does not imply activation of the p53 pathway
in this context as the p21 mRNA is also an ARE-
containing target of ZFP36L1.18,36 Given the over-
lap of the transcripts regulating the cell cycle with
those regulating the DDR, it seems probable that
ZFP36L1 and ZFP36L2 coordinate the expression
of factors involved in cell cycle progression with the
expression of factors involved in detecting or resol-
ving DNA damage.
THE CNOT COMPLEX IN EARLY
B CELL DEVELOPMENT
ZFP36 family proteins exert their mRNA-
destabilizing effects in part by recruiting the CCR4-
CNOT deadenylase complex, which interacts with
a C-terminal domain that is conserved among
ZFP36 family members through the scaffolding
component CNOT1.37,38 In addition to CNOT1,
this complex contains two deadenylases each with
two variants in mammals so the Ccr4-Cnot com-
plex may contain CNOT6 or CNOT6L and
CNOT7 or CNOT8 along with several regulatory
subunits. Two studies demonstrate that conditional
knockout of the Ccr4-CNOT complex component
Cnot3 in pro-B cells (Cnot3 cKOs) leads to
impaired B cell development.39,40 Surprisingly, how-
ever, the mechanisms described have very little
overlap with those affecting B cell development in
the absence of Zfp36l1 and Zfp36l2; in the Inoue
study CNOT3 was found to destabilize TP53
mRNA and in Cnot3 cKOs P53 was overexpressed
leading to the induction of apoptosis. P53 mRNA
abundance was not affected in pre-B cells lacking
Zfp36l1 and Zfp36l2 and there was no induction
of P53 transcriptional targets (with the exception of
p21 which as noted above is also a ZFP36L1 tar-
get) suggesting an alternative RBP is recruiting
CNOT3 to the P53 mRNA in these cells. Addition-
ally, no transcript signature relating to cell cycle
progression was enriched in Cnot3 cKO pro-B cells
suggesting that either the CCR4-NOT complex can
destabilize mRNAs independently of the CNOT3
subunit or the ZFP36 family RBPs can interact with
other mRNA-repressive complexes in pro-B cells.
As the Galloway et al. study did not characterize
the transcriptome of Zfp36l1 Zfp36l2 DCKO pro-B
cells comparison between the RNA data in these
two studies should be made with the appreciation
that each study analyzed a different population of
developing B cells.
Knockout of P53 rescued the apoptotic pheno-
type of the Cnot3 cKO pro-B cells observed by Inoue
et al., however, there was still a strong defect in V(D)J
recombination and development. This defect was
linked to decreased transcription of the IgH V genes
and decreased IgH locus contraction in Cnot3 cKOs.
These processes bring together the IgH-V gene seg-
ments and D-J gene segments making them amenable
for recombination.41 Inoue et al. demonstrated that
the expression of known transcription factors that
bring about locus contraction appeared normal in
Cnot3 deﬁcient pro-B cells. They noted that
CCR4-NOT complex has additional roles in tran-
scription and in nonsense-mediated decay (NMD)
which is required to degrade non-coding IgH mRNAs
which impede further attempts at V(D)J recombina-
tion, this could be a mechanism through which
CNOT3 might potentiate V(D)J recombination. In
contrast, the study by Yang et al. demonstrated
reduced expression of PAX5, a transcription factor
required for IgH locus contraction, in Cnot3 cKO
pro-B cells.42 Notably they did not observe an induc-
tion of P53 in their Cnot3 RERTcre cKOs and sug-
gested that the P53 induction observed by Inoue
et al. could be dependent on the genotoxic stress
induced by Mb1cre interacting with loss of Cnot3.
Yang et al. demonstrated that CNOT3 interacts with
the transcription factor EBF1 and that this interaction
is required for the expression of several EBF1 target
genes that are essential for B lineage speciﬁcation and
B cell development. A mutant EBF1 that could not
interact with CNOT3 bound less efﬁciently to
approximately half of EBF1 target genes. However,
neither Pax5 nor Ebf1 itself appeared to be sensitive
to loss of the EBF1-CNOT3 interaction. The discrep-
ancy in these results could be due to the difference in
developmental stage at which Cnot3 expression is lost
since the transcriptomics was performed on pro-B
cells isolated from RERT2cre-expressing mice follow-
ing tamoxifen treatment. CNOT3 could have slightly
different roles in the initial induction of Ebf1 and
Pax5 expression in earlier B cell progenitors. Notably
some EBF1 target genes had higher mRNA expression
in the absence of the EBF1–CNOT3 interaction, and
this was associated with increased transcript stability
indicating the role of CNOT3 in gene expression in
pro-B cells is complex and can be repressive or acti-
vating depending on the context.
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THE ROLE OF HUR IN EARLY B
AND T CELL DEVELOPMENT
The dynamic control of RNA regulons is, in princi-
ple, facilitated by the potential for RBP with the same
binding speciﬁcities to mediate distinct outcomes for
the fate of the RNA. The ARE, with its ability to
bind multiple different RBP, may be an exemplar of
this form of regulation. HuR, encoded by a paralog
of the drosophila embryonic lethal abnormal vision
gene (Elavl1), is a RNA recognition motif (RRM)
domain containing, ARE-binding protein that is pro-
posed to antagonize the destabilizing effects of the
ZFP36 family.43,44 HuR has been demonstrated to
bind to cell cycle mRNAs in an activated T cell line,
and the cell cycle is among pathways altered by loss
of HuR in activated mature B cells.45,46 Additionally,
HuR has been demonstrated to promote cell cycle
progression in cancer cell lines47–49 and can interact
with a number of transcripts that both positively and
negatively regulate cell cycle progression including
p2750–52 and Cyclin D3, the key cyclin for the prolif-
erative expansion of developing lymphocytes.53,54
Conditional deletion of Elavl1 in transplanted
bone marrow cells using a tamoxifen regulated
Rosa26CreERT2 system resulted in a large reduction
in the pro- and pre-B cell compartment and also in
immature thymocytes.55 By contrast, the deletion of
Elavl1 using Mb1cre, which is active from the pro-B
cell stage onwards, resulted in only a two-fold reduc-
tion in pre- and immature-B cells in the bone mar-
row.45,56 Deletion of Elavl1 using Lck-cre, which
deletes in double negative thymocytes also had a
milder effect on the numbers of immature thymo-
cytes.54,57 These differences could reﬂect a critical
role for HuR in B cell development prior to the pro-B
cell stage and in the earliest thymocytes. However, it
remains unclear to what extent the toxic effects of
the combination of tamoxifen and the Rosa26-
CreERT2 allele58 might have contributed to the
reductions in pro- and pre-B cells and thymocytes in
these experiments.55 Interestingly, no cell cycle defect
was detected in HuR cKO pro- or pre-B cells suggest-
ing that the cell cycle regulon regulated by ZFP36L1
and ZFP36L2 is independent of HuR in these cells.56
Other Elav family members do not appear to be
expressed in developing lymphocytes thus it may be
that other ARE-binding proteins mediate opposing
effects to the ZFP36 family in B cell development or
that no such mechanism exists in this context.4,45
In human T cells, HuR bound Ccnd3 mRNA53
and promoted expression through an effect on
mRNA stability indicating a potential role in prolifer-
ation. Furthermore, Ccnd3 mRNA was found in
HuR immuno-precipitates from mouse thymocytes
indicating that HuR may be part of a ribonucleopro-
tein complex containing Ccnd3 mRNA.54 In a mix-
ture of thymocytes subsets lacking HuR, the
abundance of Ccnd3 mRNA was unchanged but
Cyclin D3 protein abundance was reduced. Taken
together, these ﬁndings are consistent with the sug-
gestion that HuR promotes translation of Ccnd3
mRNA but the mechanism for this remains unclear.
A clear understanding of the role of HuR in the pro-
liferation in early thymocytes is complicated by dif-
ferences between published studies.54,57 Neither
study measured directly the proliferation of the
TCRβ-selected DN3 thymocytes by separation of
pre- and post-selection DN3 cells. While evidence
that HuR may promote P53 expression in thymo-
cytes could indicate a role in limiting differentiation
at the DN3 stage. It is also apparent that HuR has
role in the selection of thymocytes and in their egress
from the thymus.57 Moreover, there is evidence that
HuR functions in T cell activation and from tran-
scriptome wide studies does so by regulating many
pathways.46,59,60
THE ZFP36 FAMILY CELL CYCLE
REGULON IN OTHER PHYSIOLOGICAL
OR PATHOLOGICAL CONTEXTS
The evidence that ZFP36L1 and ZFP36L2 regulate
quiescence in developing B and T lymphocytes is
strong. It is also possible that the ZFP36 family RBP
regulate quiescence in mature lymphocytes; germinal
centre B cells undergo alternating cycles of prolifera-
tion and quiescence during afﬁnity maturation and
could use these RBP to switch between these two
states. T cell activation is accompanied by extensive
proliferation that is associated with the acquisition of
effector function. Interestingly, a global analysis of
30UTR shortening in activated T cells suggested a loss
of ZFP36 binding sites was associated with T cell
activation, consistent with an overall inhibitory func-
tion of ZFP36 family proteins in T cell activation.61
Additionally ZFP36 family RBP may regulate the cell
cycle in more diverse cell types. Deregulation of
ARE-mediated control has been associated with
malignant transformation.62 Shortening of the 30UTR
by increased usage of cleavage and polyadenylation
sites proximal to the translation stop codon, led to
loss of AREs from the 30UTR and increased abun-
dance of the coding transcript. This was associated
with increased proliferation in glioblastoma. Interest-
ingly, Cyclin D1, a target of ZFP36 was identiﬁed
amongst transcripts regulated by this mechanism.62
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A colon carcinoma cell line lacking ZFP36L1 overex-
pressed the targets Cyclin D3 and Cyclin D1 suggest-
ing many target mRNAs are shared across species
and different cellular contexts.18 The rapid depletion
of hematopoietic stem cells in germ-line knockout
Zfp36l2 mice is consistent with an accelerated stem
cell exhaustion phenotype arising from unlimited
stem cell proliferation.63,64 Loss of quiescence has
also been observed in muscle satellite cells deﬁcient in
Zfp36. In this context, ZFP36 was shown to regulate
the transcription factor MyoD which promotes pro-
liferation and differentiation of muscle satellite cells
in response to muscle damage, but this ZFP36 target
could be part of a broader regulon enforcing quies-
cence in muscle satellite cells.65 ZFP36 may also reg-
ulate the balance of quiescence and proliferation in
ﬁbroblasts as mouse embryonic ﬁbroblasts lacking
ZFP36 proliferate more.30 Notably, the targets of
ZFP36 in HEK-293 cells were overexpressed in pre-B
cells lacking Zfp36l1 and Zfp36l2 and included
many constituents of the cell cycle RNA regulon
repressed by these RBP.18,66 This suggests that target
mRNAs are commonly shared between all three
ZFP36 family members, consistent with their highly
conserved zinc ﬁnger structure. The exact activity of
ZFP36 family RBP may still depend on the cellular
context as in macrophages ZFP36 has not been
determined to regulate the cell cycle.67,68 However,
during myeloid differentiation ZFP36L1 regulates
CDK6, which, in this context, controls differentiation
to the monocyte and macrophage lineages.69 Thus,
the signiﬁcance of shared targets of these RBP is
requires knowledge of the differentiation state of the
cell and its transcriptome, as well as the expression
of other RBPs in the cell.
The prevalence of AREs within growth factors,
cell cycle progression factors, and proto-oncogenes
has prompted the hypothesis that ARE-binding pro-
teins that limit expression of these transcripts could
function as tumor suppressors. There is increasing
evidence to support this including results from cell
lines,70 animal models,19,26 and patient studies and
this has been reviewed recent by Khabar.71 Trans-
genic expression of ZFP36 inhibited the development
of B cell lymphomas in the Eμ-myc mouse tumor
model.26 However, a Zfp36l1 transgene did not
reduce disease incidence. This could reﬂect a differ-
ence in the ability of the RBP to act as tumor sup-
pressors or it could reﬂect a lower magnitude of
transgene expression.
Loss of ZFP36 correlated with poor patient
outcomes in a number of studies of different
cancers72–75 and ZFP36 inhibited cancer cell prolifer-
ation.72 By contrast, elevated expression of HuR
correlated with higher grade breast cancers (recently
reviewed by Kotta-Loizou et al.76), and might oppose
ZFP36 in this context. Bioinformatics analysis identi-
ﬁed a group of mitosis-related ARE-containing tran-
scripts that extended into those regulating the G2/M
phases of the cell cycle.73 Furthermore, the ZFP36
promoted cell cycle arrest is consistent with the
notion that transcripts encoding proteins that pro-
mote mitosis might also be repressed by the ZFP36
family (Figure 5). Although there was no evidence
for an effect on the G2-M transition in developing
lymphocytes lacking Zfp36l1 and Zfp36l2, the level
of CDK signaling as the cell exits mitosis can inﬂu-
ence the decision to enter G0 or G1 following divi-
sion77 and ZFP36 targets relevant to the G2M
transition have also been identiﬁed in other sys-
tems.78 In addition to the cell cycle, additional pro-
cesses, related to tumor growth, may also be limited
by the ZFP36 family including the epithelial-to-
mesenchymal transition and angiogenesis.79–83 Fur-
thermore, the ability of the ZFP36 family to suppress
inﬂammation may contribute to a microenvironment
less conducive to tumor development.84 It will be
interesting to see if in mouse models in which ZFP36
activity is enhanced, either though removal of the
inhibitory phosphorylation sites,85 or through
removal of the auto-inhibitory feedback that acts via
the ARE in the Zfp36 mRNA 30UTR,86 the develop-
ment of cancer is forestalled.
Here, we have discussed examples of RNA regu-
lons that coordinate important processes in lympho-
cyte development. Several challenges must be faced to
advance our understanding of RNA regulons in lym-
phocyte development and other biological contexts.
Many RBPs share sequence speciﬁcity for simple
motifs such as the ARE and this can make studying
their functions challenging, for example, all three
ZFP36 family members are expressed in developing T
and B cells and KO of two family members is required
to have dramatic effects on early lymphocyte cell
development. This ‘redundancy’ was also observed in
lymphomagenesis: T cell acute lymphoblastic leuke-
mia develops in Zfp36l1 Zfp36l2 double cKOs, but
not in the absence of only one family member. In this
context, Zfp36 was unable to compensate for the loss
of Zfp36l1 and Zfp36l2. In contrast, although there
are four members in the HuR family, only HuR is
expressed in B cells, but it may still compete with
other RRM-containing or ARE-binding RBP from
other families. The mis-expression of the HuR rela-
tive HuD in thymocytes expressing constitutively
active NOTCH3 caused mis-splicing of the transcrip-
tion factor Ikaros (Ikzf1) into short dominant nega-
tive forms that promote cell cycle progression and
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lymphomagenesis,87 indicating that related family
members may also have very different effects on
development. A further challenge is to make sense of
the functional interactions between AREs, their bind-
ing proteins, and non-coding RNAs such as
microRNAs, long non-coding RNAs, and circular
RNAs. We anticipate that these interactions will
either promote or inhibit the expression of protein
coding genes and will themselves be highly regulated
and relevant to pathology.88–91 If better understood,
it is possible that these interactions may be exploited
as new therapeutic modalities.92,93 Studies describing
the roles of RBP tend to focus on one or a few major
targets, however, since all RBP investigated so far
appear to have many RNA targets it is important to
try to understand how effects on several targets help
to shape the transcriptome. This is easier when the
pathways regulated by the RBP are well described, as
is the case with regulation of the G1-S transition,
where many of the interactions between several key
proteins are known, aiding our understanding of
how they cooperate within an RNA regulon. How-
ever, it still remains challenging to carefully validate
more than a few key targets. It will also be important
to validate the signaling pathways that regulate RBP
function in the speciﬁc biological contexts where the
RBPs are found to function. This is because most of
the early work describing signaling and interaction
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between RBP and effector complexes has been under-
taken in transformed cell lines where the RBP may be
inappropriately regulated by oncogenes. In this con-
text, it is clear that many signaling pathways con-
verge on RBPs including phosphorylation, protein
methylation and acetylation, ubiquitination, prolyl-
isomerization, ADP-ribosylation, and proteolysis.
These may affect the composition and function of
ribonucleoprotein complexes in ways that are, with
our current state of knowledge, difﬁcult to predict.94
There may also be context-dependent differ-
ences in transcript structure caused by alternative
splicing and alternative polyadenylation as well as
enzymatic modiﬁcation that allow transcripts to
include or exclude certain regulatory elements.95 We
observed that several annotated transcripts fall short
of the full 30UTR length while investigating the AREs
in cell cycle regulators, notably, some of these have
since been updated, however, it seems likely that
determining transcript structures within the cells of
interest will be helpful when considering regulatory
sequences. The recognition of the importance of
post-transcriptional regulation of RNA operons
should fuel attempts to master these challenges.
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